Denileukin diftitox

地尼白介素2

Report date: 2026/03/13 20:02:36
First In Class

Base Information

Drug NameDenileukin diftitox
Drug Alias NameInterleukin-2 diphtheria toxin fusion protein地托-迪尼白介素-2Interleukin-2 fusion toxinDenileukinum diftitoxumDenileukina diftitox +[14] 
ClassificationBiologics > Protein drugs > ToxinBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionProtein biosynthesis inhibitorsInterleukin-2 receptor modulators
TargetsInterleukin-2 receptor
Therapy Area/IndicationsSkin MelanomaSolid tumoursKidney Neoplasms +[31] 
Global Approved IndicationsLymphoma, T-Cell, Cutaneous
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1999/02/05
Country/TerritoryCanadaUnited StatesPuerto Rico +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesEisai Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesEisai IncCitius Pharmaceuticals IncDr.Reddy's Laboratories Ltd
Inactive CompaniesUT Health San AntonioWake Forest University Health SciencesMasonic Cancer Center, University Of Minnesota +[12] 
Active IndicationsLymphoma, T-Cell, Cutaneous
Inactive IndicationsSkin MelanomaSolid tumoursKidney Neoplasms +[30] 

Other Information

ATC CodeL01XX29
Related LinksWikipediaDrugBankKEGG